Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Takeda Gives Mellinnium Task To Select Best Cancer Drug Candidates

This article was originally published in PharmAsia News

Executive Summary

Takeda Pharmaceutical is turning over the decision-making about its pipeline of oncology drugs to its American biotech subsidiary, Millennium Pharmaceuticals. Takeda has 15 drugs for treating cancer in clinical trials, but has decided to let Mellinnium draw on its expertise and technology to select the best candidates from among them and speed their development. Takeda is more familiar with hypertension and diabetes drugs, but several best-sellers in those groups face patent expirations next year. (Click here for more - a subscription may be required



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts